



GeneTether Therapeutics Inc. Receives Notice of Allowance from USPTO

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Vancouver, British Columbia – February 14, 2022 – GeneTether Therapeutics Inc., an EGB Ventures portfolio company (“**GeneTether**” or the “**Company**”), announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent entitled “Modified Nucleic Acid Editing Systems for Tethering Donor DNA” related to its GeneTether platform technology. Upon issuance, it is expected that the standard 20 year patent term will extend to March 2039.

An amended and restated preliminary prospectus dated January 27, 2022 containing important information relating to an offering of a minimum of \$4.5 million of units of the Company has been filed with the securities commissions or similar authorities in certain jurisdictions of Canada. The amended and restated preliminary prospectus is still subject to completion or amendment. Copies of the preliminary prospectus may be obtained from Research Capital Corporation. There will not be any sale or any acceptance of an offer to buy the securities until a receipt for the final prospectus has been issued.

About GeneTether

Founded by EGB Ventures founder and managing partner, William J. Garner, M.D., and veteran gene editing researcher, R. Geoffrey Sargent, Ph.D., GeneTether is focused on developing its disruptive proprietary platform technology to significantly increase the efficiency of DNA insertion into the genome for gene correction and complementation strategies. The Company’s wholly-owned platform technology uses a proprietary method to “tether” donor DNA templates to the genome editing complex, making the template readily available for use during the genome editing repair stage. The Company is leveraging its platform technology to develop curative therapies for the treatment of rare genetic diseases. GeneTether’s proof of concept study demonstrated an approximately 7x higher gene editing efficiency as compared to the same gene editing payload without application of GeneTether’s technology.

For more information, visit www.genetether.com.

Contacts:

Roland Boivin, CEO
GeneTether Therapeutics Inc.
(833) 294-4363 ext. 1
roland@genetether.com

Jean Jen, CFO
GeneTether Therapeutics Inc.
(833) 294-4363 ext. 2
jean@genetether.com

Forward-Looking Disclaimer

Certain information in this news release constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans," "targets," "expects" or "does not expect," "is expected," "an opportunity exists," "is positioned," "estimates," "intends," "assumes," "anticipates" or "does not anticipate" or "believes," or variations of such words and phrases or state that certain actions, events or results "may," "could," "would," "might," "will" or "will be taken," "occur" or "be achieved." In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information, including statements regarding the expected timing for expiration of the Company's patent once granted. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by GeneTether as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of GeneTether's amended and restated preliminary prospectus dated January 27, 2022 available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect GeneTether; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and GeneTether expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Neither the TSXV nor its regulation services provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.